ADAP Advocacy Blasts FDA on Florida’s Drug Importation Approval

Federal agency’s approval of the risky drug importation plan potentially puts the health of people living with HIV at risk

For Immediate Release: Media Contact: January 5, 2023 info@adapadvocacy.org

WASHINGTON, D.C. – ADAP Advocacy today issued the following statement by CEO Brandon M. Macsata:

“ADAP Advocacy is disturbed by the U.S. Food & Drug Administration’s deeply flawed decision to approve Florida’s plan to import prescription drugs from Canada. This policy is a particularly acute threat to people living with HIV in the United States and Canada since the list of drugs Florida intends to import includes a disproportionate number of treatments for HIV. Additionally, the safety of HIV medicine has already been in question following one of the largest counterfeiting schemes in our nation’s history. Given Canada’s expressed concerns about participating in importation plans, we are worried patients in Florida will now be at even greater risk for counterfeits. We urge the FDA to reconsider approving Florida’s Canadian drug importation program.”

To learn more about ADAP Advocacy, AIDS Drug Assistance Programs, or the dangers of drug importation, please email info@adapadvocacy.org.

####

About ADAP Advocacy: ADAP Advocacy’s mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.